Patents Issued in April 30, 2020
  • Publication number: 20200131217
    Abstract: The invention relates to dendritic compounds, the use of these compounds as pharmaceuticals, pharmaceutical and cosmeceutical compositions containing the compounds, and methods of treating cancer, inflammation, diabetic nephropathy, neurodegenerative disorders, Niemann-Pick Type C disease, or dermatological conditions.
    Type: Application
    Filed: March 23, 2017
    Publication date: April 30, 2020
    Inventors: Jeremy E. TURNBULL, Andrew MUNKACSI, Peter Charles TYLER, Olga Vladimirovna ZUBKOVA
  • Publication number: 20200131218
    Abstract: Compounds described herein are mithramycin (MTM) oxide (OX) derivatives and MTM Hydrazine (HY) derivatives. These compounds are useful for treatment of cancers and neuro-diseases.
    Type: Application
    Filed: October 31, 2019
    Publication date: April 30, 2020
    Inventors: Jon S. Thorson, Jurgen Rohr, Markos Leggas, Joseph M. Eckenrode, Yinan Zhang, Yang Liu, Jianjun Zhang, Khaled Attia Shaaban Mahmoud
  • Publication number: 20200131219
    Abstract: The present invention relates to the novel use of saponins having acetyl residues on one of their sugar residues. These saponins are able to enhance the transfection efficiency to a surprisingly much higher extent than already known saponins and even than Lipofectamin.
    Type: Application
    Filed: July 10, 2018
    Publication date: April 30, 2020
    Applicant: Freie Universität Berlin
    Inventors: Alexander Weng, Matthias F. Melzig, Simko Sama
  • Publication number: 20200131220
    Abstract: Cyphomycin, an isolated compound of Formula I or IA is provided. A compound isolated from insect Streptomyces and having a chemical formula of C77H122O26 is also provided. Compositions including Cyphomycin, such as pharmaceutical compositions including effective amounts of Cyphomycin for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with Cyphomycin and compositions thereof are disclosed.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 30, 2020
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Timothy S. Bugni, Monica Tallarico Pupo, David R. Andes, Cameron R. Currie, Humberto Enrique Ortega Dominguez
  • Publication number: 20200131221
    Abstract: The invention relates to the wood chemical industry and concerns a method for extracting phytosterols from tall oil pitch. The present method of extracting phytosterols from tall oil pitch involves saponifying tall oil pitch using an alkali in a polyatomic alcohol, extracting unsaponified matter from the alkali-alcohol solution using a hydrocarbon solvent, subsequently removing the solvent by distillation, and concentrating the phytosterols, wherein a mixture of paraffin hydrocarbons is used as said hydrocarbon solvent, and, following extraction from the extraction solution, betulin is isolated by crystallization and the phytosterols are then concentrated by means of rectification. This method makes it possible to increase the rate of extraction of phytosterols from saponified tall oil pitch to up to 95% and allows an end product to be produced that has a phytosterol content of at least 65% with unwanted betulin impurities at no more than 0.3%.
    Type: Application
    Filed: May 8, 2018
    Publication date: April 30, 2020
    Applicant: ORGKHIM BCH MANAGEMENT COMPANY, JSC
    Inventors: Ilia Nikolaevich CHERNOV, Alexey Olegovich KORSHUNOV, Taras Ivanovich DOLINSKIY, Mikhail Alekseevich LAZAREV, Ekaterina Aleksandrovna MAVRINA, Ilia Sergeevich ILICHEV, Arkadiy Benyuminovich RADBIL
  • Publication number: 20200131222
    Abstract: The present specification relates to a composition containing novel (20S,24R)-6-O-?-D-glucopyranosyl(1->2)-?-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, a pharmaceutically acceptable salt thereof, a hydrate or a solvate thereof as an active ingredient. The composition exhibits an excellent exercise ability enhancing effect and anti-fatigue effect.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 30, 2020
    Applicant: AMOREPACIFIC CORPORATION
    Inventors: Yong Deog HONG, Hyun Woo JEONG
  • Publication number: 20200131223
    Abstract: The invention relates to compounds, compositions and polymers comprising a first component adapted to promote germination of Clostridium difficile (C. diff) and a second component which acts as an antimicrobial agent. Said compounds, compositions and polymers are useful for destroying C. diff where conventional antimicrobial agents are unsuccessful. The compositions can be formulated as coating or materials which actively destroy C. diff which come into contact with it. The germination promotion is induced by bile salts. The invention also relates to the use of such materials as a treatment for C. diff associated diseases and toxic megacolon.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Inventors: Daniel Lee Rathbone, Tony Worthington, Sahar Al-Malaika, Matthew Justin Hird, Alexandria Rose Quayle
  • Publication number: 20200131224
    Abstract: The present disclosure relates to the synthesis of radionuclide complex solutions, in particular for their use in the commercial production of radioactive drug substances, for diagnostic and/or therapeutic purposes. In particular, the synthesis method comprises the following steps in the following order: a. providing a radionuclide precursor solution into a first vial, b. transferring the radionuclide precursor solution into a reactor, c. providing a reaction buffer solution into said first vial containing residual radionuclide precursor solution, d. transferring the buffer reaction solution and residual radionuclide precursor solution from said first vial into the reactor, e. transferring a peptide solution comprising the somatostatin receptor binding peptide linked to a chelating agent, into the reactor, f. reacting the somatostatin receptor binding peptide linked to a chelating agent with said radionuclide in the reactor to obtain the radionuclide complex, g. recovering said radionuclide complex.
    Type: Application
    Filed: April 24, 2019
    Publication date: April 30, 2020
    Applicant: Advanced Accelerator Applications (Italy) S.R.L.
    Inventors: Lorenza Fugazza, Francesco De Palo, Donato Barbato, Maurizio F. Mariani, Giovanni Tesoriere, Clementina Brambati
  • Publication number: 20200131225
    Abstract: The present invention provides a chromatographic separation method for improving the quality of albumin fusion protein solutions by removing impurities from the albumin fusion protein solution. This invention provides albumin fusion protein solution with a significantly reduced amount of the (yellow) coloured impurities and HCP.
    Type: Application
    Filed: April 19, 2018
    Publication date: April 30, 2020
    Inventors: Viveka Dolby, Are Bogsnes
  • Publication number: 20200131226
    Abstract: A system and method for producing high levels of autologous IL-1RA cytokine, includes a blood collection vessel, a cover, a portion of separation gel, an anticoagulant portion, a plasma collection syringe comprising a sharp needle, a buffy coat collection syringe and an incubation tube with cover. The blood collection vessel is adapted such that when containing whole blood and being centrifuged, after treatment yields separation fractions comprising, a first fraction of RBCs sediment, a second fraction of said gel, a third fraction comprising WBCs, platelets and a fourth fraction of plasma solution.
    Type: Application
    Filed: December 30, 2019
    Publication date: April 30, 2020
    Applicant: Estar Technologies Ltd
    Inventor: Aaron Esteron
  • Publication number: 20200131227
    Abstract: The present invention relates to a polypeptide with tumor binding activity, and its use in the treatment and diagnosis of cancer.
    Type: Application
    Filed: February 27, 2018
    Publication date: April 30, 2020
    Inventors: Uwe HABERKORN, Walter MIER, Max SAUTER, Annette ALTMANN, Christel HEROLD-MENDE, Rolf WARTA, Saskia RÖSCH
  • Publication number: 20200131228
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 23, 2019
    Publication date: April 30, 2020
    Inventors: Paul Beswick, Gemma Elizabeth Mudd, Kevin McDonnell, Gabriela Ivanova-Berndt, Katerine Van Rietschoten, David Witty, Michael Skynner
  • Publication number: 20200131229
    Abstract: The present invention discloses a method for promoting B. subtilis to synthesize surfactin based on multi-gene synergy, and belongs to the field of genetic engineering. Firstly, B. subtilis is enabled to obtain the ability to synthesize surfactin by integrant expression of sfp protein derived from a high-yield strain, on this basis, by knocking out genes associated with a competitive pathway, overexpressing genes associated with the surfactin tolerance of B. subtilis, strengthening genes associated with a branched chain fatty acid synthesis pathway or improving the intracellular srfA gene transcription level, the synergy among genes is realized, and systemic metabolic engineering transformation is performed on the B. subtilis, thereby greatly improving the ability of B. subtilis genetically engineered bacteria to synthesize surfactin. Compared with a starting strain B. subtilis 168, the amount of extracellular accumulation of surfactin of the B.
    Type: Application
    Filed: December 14, 2018
    Publication date: April 30, 2020
    Inventors: Qun WU, Yan XU
  • Publication number: 20200131230
    Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.
    Type: Application
    Filed: September 13, 2017
    Publication date: April 30, 2020
    Applicants: Daiichi Sankyo Company, Limited, PeptiDream Inc.
    Inventors: Takahiro YAMAGUCHI, Yutaka MORI, Hironao SAITO, Hideki KUBOTA, Akihiro FURUKAWA, Eri OTSUKA, Yutaka ISHIGAI, Hiroshi IJIRI, Patrick REID
  • Publication number: 20200131231
    Abstract: The present invention relates to peptides, in particular cell penetrating peptides, of 40 amino acid residues or less comprising at least one directly glycosylated amino residue and one or more arginine rich arm domains, and to conjugates of such cell penetrating peptides with a therapeutic molecule. The present invention further relates to the use of the peptides or conjugates in methods of treatment or as a medicament, especially in the treatment of genetic disorders of the central nervous system. page.
    Type: Application
    Filed: February 16, 2018
    Publication date: April 30, 2020
    Inventors: Matthew Wood, Suzan Hammond, Melissa Bowerman, Michael Gait, Frank Adendroth, Graham McClorey
  • Publication number: 20200131232
    Abstract: A composition-of-matter comprising a crystallized form of a large ribosomal (50S) subunit of a pathogenic bacterium, and the atomic coordinates of the three-dimensional structure thereof are provided herein, as well as methods for crystallizing the same, and using the atomic coordinates of the same to design de novo ligands with high specificity thereto.
    Type: Application
    Filed: December 24, 2019
    Publication date: April 30, 2020
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Ada YONATH, Zohar EYAL, Donna MATZOV, Haim ROZENBERG, Ella ZIMMERMAN, Anat BASHAN
  • Publication number: 20200131233
    Abstract: The present invention relates to a two-part linker comprising a peptide tag (peptide) and a polypeptide (protein) that is capable of spontaneously forming an isopeptide bond, particularly wherein: a) said peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1, wherein: (i) X at position 1 is arginine or no amino acid; (ii) X at position 2 is glycine or no amino acid; (iii) X at position 5 is histidine or threonine; (iv) X at position 11 is alanine, glycine or valine; and (v) X at position 14 is arginine or lysine, wherein when X at position 1 is no amino acid, X at position 2 is no amino acid; and b) said polypeptide comprises: i) an amino acid sequence as set forth in SEQ ID NO: 2; ii) a portion of (i) comprising an amino acid sequence as set forth in SEQ ID NO: 101; iii) an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 2, wherein said amino acid sequence comprises a lysine at position 34, a glutamic acid at position 80 and one or more of the
    Type: Application
    Filed: April 24, 2018
    Publication date: April 30, 2020
    Inventors: Mark HOWARTH, Anthony KEEBLE
  • Publication number: 20200131234
    Abstract: Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression.
    Type: Application
    Filed: October 8, 2019
    Publication date: April 30, 2020
    Applicants: UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jean-Philippe COMBIER, Dominique LAURESSERGUES, Guillaume BECARD, François PAYRE, Serge PLAZA, Jérôme CAVAILLE
  • Publication number: 20200131235
    Abstract: Provided are a recombinant group 2 allergen protein from Dermatophagoides pteronyssinus, and an encoding gene and preparation method thereof. The encoding gene is obtained by preforming codon optimization on a wild-type encoding gene of a group 2 allergen protein from Dermatophagoides pteronyssinus and is beneficial to expression in Pichia pastoris. Further, an acting element increasing target protein expression is added to the expression system.
    Type: Application
    Filed: December 28, 2017
    Publication date: April 30, 2020
    Inventors: Bruce Yong MA, Yu FAN, Anliang WANG, Jun WANG
  • Publication number: 20200131236
    Abstract: Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Inventors: Greg Petsko, Dagmar Ringe, Shulin Ju
  • Publication number: 20200131237
    Abstract: Provided herein are compositions, systems, kits, and methods for treating nervous system injuries caused by trauma or neurodegeneration or aging in a subject by administering a CSPG or SOCS3 reduction peptide (CRP and SRP respectively), or a nucleic acid sequence encoding the CRP or SRP, wherein both the CRP and SRP comprise a cell membrane penetrating domain, and a lysosome targeting domain, and the CRP further comprises a chondroitin sulfate proteoglycan (CSPG) binding domain, and the SRP further comprises a suppressor of cytokine signaling-3 (SOCS3) binding domain.
    Type: Application
    Filed: June 26, 2018
    Publication date: April 30, 2020
    Inventors: Yu-Shang Lee, Ching-Yi Lin
  • Publication number: 20200131238
    Abstract: Here we show that epigenetic control of Neuregulin-1 (NRG1) affects adipose differentiation of stem cells in vitro. Building on this finding, we established a model in which NRG1 is a white adipose tissue (WAT) specific regulator analogous to the role of NRG4 in black adipose tissue (BAT). In this light, NRG1 functions in a paracrine or autocrine manner to regulate formation of new adipocytes from stem populations, both in vitro and in vivo. In neurons, NRG1 has been shown already to play a similar role, promoting neuronal cell differentiation from progenitors in the vertebrate cortex and retina and even promoting neuronal differentiation in vitro. Similarly, in the heart, NRG1 promotes differentiation of cardiomyocytes from their stem cell progenitors both in vivo and in vitro and for this reason has been successfully tested in clinical trials for heart failure.
    Type: Application
    Filed: October 24, 2019
    Publication date: April 30, 2020
    Inventor: John R. BRACHT
  • Publication number: 20200131239
    Abstract: The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex.
    Type: Application
    Filed: June 13, 2017
    Publication date: April 30, 2020
    Applicant: Torque Therapeutics, Inc.
    Inventors: Ferdinando PUCCI, Thomas Lars ANDRESEN, Douglas Scott JONES, Ulrik NIELSEN, James Andrew RAKESTRAW
  • Publication number: 20200131240
    Abstract: The present invention relates to the use of exogenous interleukin-12 (IL-12) for increasing endogenous production of erythropoietin.
    Type: Application
    Filed: December 23, 2019
    Publication date: April 30, 2020
    Inventor: Lena A. Basile
  • Publication number: 20200131241
    Abstract: Type I interferon (IFN-I) signatures are useful in methods of diagnosing whether a subject (or patient) with IFN-I mediated disease will be responsive to treatment with an IFN-I inhibitor and treating or refraining from treating the subjects.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 30, 2020
    Inventors: Matteo Cesaroni, Marc Chevrier, Jarrat Jordan, Jessica Schreiter
  • Publication number: 20200131242
    Abstract: Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing weight loss or body fat reduction, methods of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.
    Type: Application
    Filed: July 15, 2019
    Publication date: April 30, 2020
    Applicant: OPKO BIOLOGICS LTD.
    Inventors: Fuad FARES, Udi Eyal FIMA
  • Publication number: 20200131243
    Abstract: The present disclosure relates generally to compositions of insulin-Fc (e.g., proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g., autoimmune diabetes, e.g., Type 1 diabetes.
    Type: Application
    Filed: December 8, 2017
    Publication date: April 30, 2020
    Applicant: Akston Biosciences Corporation
    Inventors: Thomas M. Lancaster, Todd C. Zion, Thillainayagam Sathiyaseelan, Sylaja Murikipudi
  • Publication number: 20200131244
    Abstract: Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments.
    Type: Application
    Filed: March 27, 2018
    Publication date: April 30, 2020
    Inventors: Jun Hao Leong, Noriko Shimasaki, See Voon Seow, Dario Campana, James Barnaby Trager, Alexandra Leida Liana Lazetic, Chao Guo, Luxuan Guo Buren, Shyam Sashikant Masrani
  • Publication number: 20200131245
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Application
    Filed: January 8, 2020
    Publication date: April 30, 2020
    Applicant: ZYMOGENETICS, INC.
    Inventors: Carl W. BIRKS, Brian A.. FOX, Mark W. RIXON, Jeff L. ELLSWORTH
  • Publication number: 20200131246
    Abstract: Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.
    Type: Application
    Filed: January 10, 2020
    Publication date: April 30, 2020
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Eric FURFINE, Daniel DIX, Kenneth GRAHAM, Kelly FRYE
  • Publication number: 20200131247
    Abstract: The present invention relates to modified proteins e.g. oxygen-carrying proteins, with improved or enhanced, in comparison to a reference protein, reduction of a metal ion associated with the modified protein. The present invention also relates to methods of using such modified proteins and compositions comprising such proteins e.g. in therapy.
    Type: Application
    Filed: March 13, 2018
    Publication date: April 30, 2020
    Inventors: Chris E. Cooper, Brandon Reeder, Gary Silkstone
  • Publication number: 20200131248
    Abstract: The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord injury, SCI).
    Type: Application
    Filed: October 29, 2019
    Publication date: April 30, 2020
    Inventors: Christoph KLEINSCHNITZ, Marc NOLTE, Anna-Leena SIRÉN, Christiane ALBERT-WEISSENBERGER, Sarah HOPP-KRAEMER
  • Publication number: 20200131249
    Abstract: The invention relates to proteins containing any of the sequences according to general formula (Ih): X1CRX2X3X4X5??(Ih) where X1 is F, Y, L, P, Q, M, V, W, A, T and X2 is A, G, S, T and X3 is V, A, I, L, M, D, H, S and X4 is K, I, Q, R, H, S, F, M, N, L, V and X5 is R, V, I, K, M, Q, E, F, L, N, Y, D, S, H. and its salts, esters and pharmaceutically acceptable prodrugs. The invention further relates to pharmaceutical preparations and kits containing said proteins, to screening procedures using said proteins. The proteins of the invention are useful in the treatment or prevention of diseases that can be treated by inhibiting the complement system.
    Type: Application
    Filed: January 4, 2018
    Publication date: April 30, 2020
    Applicant: EVOLVERITAS KFT.
    Inventors: Peter GAL, Gabor PAL, David SZAKACS
  • Publication number: 20200131250
    Abstract: The inventors discovered that viscosity of a protein solution can be estimated by measuring the apparent particle size or apparent molecular weight by a small angle X-ray scattering (SAXS) method or X-ray solution scattering method, which enables measurement of small amounts of samples, and then correlating those measurement results with viscosity of the protein solution.
    Type: Application
    Filed: January 14, 2020
    Publication date: April 30, 2020
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Masakazu Fukuda, Akira Hayasaka, Tomoyuki Igawa, Atsuhiko Maeda, Machiko Fujino
  • Publication number: 20200131251
    Abstract: The invention describes an efficient platform for antibody manufacturing and formulation that provides i) cell culture process with improved feeding strategy resulting in high antibody titer between 2 gm/L to 5 gm/L; ii) improved purification process showing optimal percentage recovery, high purity monomer content, minimum aggregation/particulate formation, minimum impurity levels; and iii) high concentration stable liquid formulation with optimal osmolality and low viscosity across different temperature excursions and devoid of aggregation. The preferred antibodies include IgG1 monoclonal antibody specific to the Dengue virus epitope in domain III of the E protein and IgG1 monoclonal antibody specific to the rabies virus surface G glycoprotein.
    Type: Application
    Filed: December 20, 2017
    Publication date: April 30, 2020
    Inventors: Dhere Rajeev MHALASAKANT, Pisal Sambhaji SHANKAR, Peddi Reddy Srinivas REDDY, Singh Digamber CHAHAR, Yeolekar Leena RAVINDRA, Chouhan Pankaj SINGH, Avalaskar Nikhil DATTATRAY
  • Publication number: 20200131252
    Abstract: Antibodies having Fab regions that specifically bind to Staphylococcus aureus protein A are capable of mediating opsinization of Staphylococcus aureus bacteria despite their expression of antibody-neutralizing protein A. These antibodies and antigen-binding fragments thereof can be used in methods of treating and/or preventing Staphylococcus aureus infections.
    Type: Application
    Filed: January 8, 2020
    Publication date: April 30, 2020
    Inventor: John Simard
  • Publication number: 20200131253
    Abstract: Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described.
    Type: Application
    Filed: April 30, 2019
    Publication date: April 30, 2020
    Inventors: Paul PARREN, Patrick VAN BERKEL, Ewald VAN DEN BREMER
  • Publication number: 20200131254
    Abstract: The disclosure relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 30, 2020
    Inventors: Michael J. Comb, John Edward Rush, II, Jing Li, Ailan Guo
  • Publication number: 20200131255
    Abstract: The invention provides methods of treating tauopathies with anti-Tau antibodies.
    Type: Application
    Filed: September 19, 2019
    Publication date: April 30, 2020
    Applicant: Genentech, Inc.
    Inventors: Geoffrey Kerchner, Edmond Teng
  • Publication number: 20200131256
    Abstract: Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine.
    Type: Application
    Filed: November 22, 2019
    Publication date: April 30, 2020
    Inventors: Chetankumar Natvarlal Patel, Michael Parvin Johnson, Catherine Brautigam Beidler
  • Publication number: 20200131257
    Abstract: The present invention relates in one aspect to the discovery that ?-Klotho is the primary cell-surface receptor for FGF21, with FGFR1c functioning as a catalytic subunit that ultimately mediates intracellular signaling. In one aspect, the invention provides compositions and methods that are useful in treating or preventing endocrine FGF-related diseases or disorders.
    Type: Application
    Filed: July 5, 2018
    Publication date: April 30, 2020
    Inventors: Joseph Schlessinger, Sangwon Lee
  • Publication number: 20200131258
    Abstract: An scFv-Fc dimer binds and neutralizes TGF?1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGF?1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications.
    Type: Application
    Filed: October 30, 2019
    Publication date: April 30, 2020
    Applicant: GENZYME CORPORATION
    Inventors: Huawei Qiu, Clark Pan, Julie Bird
  • Publication number: 20200131259
    Abstract: Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-? superfamily of proteins.
    Type: Application
    Filed: January 7, 2020
    Publication date: April 30, 2020
    Inventors: Thomas Schurpf, Nagesh K. Mahanthappa, Michelle Marie Straub
  • Publication number: 20200131260
    Abstract: The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.
    Type: Application
    Filed: January 13, 2020
    Publication date: April 30, 2020
    Applicants: AskGene Pharma Inc., Jiangsu Aosaikang Pharmaceutical Co., Ltd.
    Inventors: Yuefeng Lu, Jian-Feng Lu
  • Publication number: 20200131261
    Abstract: The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute or chronic inflammatory disease, etc. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto.
    Type: Application
    Filed: April 18, 2018
    Publication date: April 30, 2020
    Inventors: Jung Ho Kim, Beom Seok Kim
  • Publication number: 20200131262
    Abstract: The present invention relates to a targeting module comprising a chemically synthesized peptide binding moiety specific for a human cell surface protein or protein complex, a kit comprising the targeting module and a vector or a cell comprising a nucleic acid encoding a universal chimeric antigen receptor and the use for the treatment of cancer, infections and autoimmune disorders.
    Type: Application
    Filed: June 8, 2018
    Publication date: April 30, 2020
    Applicant: GEMoaB Monoclonals GmbH
    Inventor: Armin EHNINGER
  • Publication number: 20200131263
    Abstract: Provided are an anti-GITR antibody, an antigen-binding fragment thereof, and pharmaceutical uses thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR of the anti-GITR antibody, a pharmaceutical composition containing the anti-GITR antibody or the antigen-binding fragment thereof, and use of the anti-GITR antibody in preparation of an anti-cancer drug. In particular, provided is a humanized anti-GITR antibody, and its use in the preparation of drugs for treating GITR-mediated diseases or disorders.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 30, 2020
    Inventors: Shude YAN, Jiahua JIANG, Hao HUANG, Lianshan ZHANG, Guoqing CAO
  • Publication number: 20200131264
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Application
    Filed: March 3, 2017
    Publication date: April 30, 2020
    Applicant: Alector LLC
    Inventors: Andrew Pincetic, Arnon Rosenthal, Helen Lam, Francesca Avogadri-Connors, Seung-Joo Lee
  • Publication number: 20200131265
    Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
    Type: Application
    Filed: June 11, 2019
    Publication date: April 30, 2020
    Applicant: MacroGenics, Inc.
    Inventors: Scott Koenig, Maria Concetta Veri
  • Publication number: 20200131266
    Abstract: Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Also included are molecules having an antigen binding fragment that immunospecifically bind to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Also provided are methods for treating anti-PD-1 therapy or anti-PD-L1 therapy resistant or refractory cancers.
    Type: Application
    Filed: May 30, 2018
    Publication date: April 30, 2020
    Inventors: Stephen Sunghan Yoo, Yong-Sik Bong, Kyu Lee Han, Michael Joseph Surace